327 related articles for article (PubMed ID: 2998370)
1. Inhibition of transmembrane movement and metabolism of platelet activating factor (PAF-acether) by a specific antagonist, BN 52021.
Lachachi H; Plantavid M; Simon MF; Chap H; Braquet P; Douste-Blazy L
Biochem Biophys Res Commun; 1985 Oct; 132(2):460-6. PubMed ID: 2998370
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba.
Lamant V; Mauco G; Braquet P; Chap H; Douste-Blazy L
Biochem Pharmacol; 1987 Sep; 36(17):2749-52. PubMed ID: 2820421
[TBL] [Abstract][Full Text] [Related]
3. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds.
Baroggi N; Etienne A; Braquet P
Agents Actions Suppl; 1986; 20():87-97. PubMed ID: 3028108
[TBL] [Abstract][Full Text] [Related]
4. Effect of BN 52021, a specific antagonist of platelet activating factor (PAF-acether), on calcium movements and phosphatidic acid production induced by PAF-acether in human platelets.
Simon MF; Chap H; Braquet P; Douste-Blazy L
Thromb Res; 1987 Feb; 45(4):299-309. PubMed ID: 3576518
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three paf-acether receptor antagonist ginkgolides.
Korth R; Nunez D; Bidault J; Benveniste J
Eur J Pharmacol; 1988 Jul; 152(1-2):101-10. PubMed ID: 2850196
[TBL] [Abstract][Full Text] [Related]
6. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
[TBL] [Abstract][Full Text] [Related]
7. Effects of platelet-activating factor on electrophysiology of isolated retinas and their inhibition by BN 52021, a specific PAF-acether receptor antagonist.
Doly M; Bonhomme B; Braquet P; Chabrier PE; Meyniel G
Immunopharmacology; 1987 Jun; 13(3):189-94. PubMed ID: 3038784
[TBL] [Abstract][Full Text] [Related]
8. Species difference in the specific receptors of platelet activating factor.
Hwang SB; Lam MH
Biochem Pharmacol; 1986 Dec; 35(24):4511-8. PubMed ID: 3024653
[TBL] [Abstract][Full Text] [Related]
9. BN 52021 displaces [3H]paf-acether from, and inhibits its binding to intact human platelets.
Korth R; Benveniste J
Eur J Pharmacol; 1987 Oct; 142(3):331-41. PubMed ID: 3428349
[TBL] [Abstract][Full Text] [Related]
10. Proof of the involvement of platelet activating factor (paf-acether) in pulmonary complex immune systems using a specific paf-acether receptor antagonist: BN 52021.
Touvay C; Vilain B; Taylor JE; Etienne A; Braquet P
Prog Lipid Res; 1986; 25(1-4):277-88. PubMed ID: 2827186
[No Abstract] [Full Text] [Related]
11. Species-dependent differences of high affinity [3H]PAF-binding to platelets from humans and pigs and its inhibition by selected antagonists.
Ostermann G; Lorenz A; Hofmann B; Kertscher HP
J Lipid Mediat; 1991 Nov; 4(3):289-98. PubMed ID: 1662546
[TBL] [Abstract][Full Text] [Related]
12. Inhibition by BN 52021 (ginkgolide B) of the binding of [3H]-platelet-activating factor to human neutrophil granulocytes.
Földes-Filep E; Braquet P; Filep J
Biochem Biophys Res Commun; 1987 Nov; 148(3):1412-7. PubMed ID: 2825685
[TBL] [Abstract][Full Text] [Related]
13. Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.
Domingo MT; Piro F; Broquet C; Auclair E; Chabrier PE; Braquet P
Lipids; 1992 Aug; 27(8):582-6. PubMed ID: 1328798
[TBL] [Abstract][Full Text] [Related]
14. The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021.
Baranes J; Hellegouarch A; Le Hegarat M; Viossat I; Auguet M; Chabrier PE; Braquet P
Pharmacol Res Commun; 1986 Aug; 18(8):717-37. PubMed ID: 3763677
[TBL] [Abstract][Full Text] [Related]
15. Interference of BN 52021 (ginkgolide B) with the bronchopulmonary effects of PAF-acether in the guinea-pig.
Desquand S; Touvay C; Randon J; Lagente V; Vilain B; Maridonneau-Parini I; Etienne A; Lefort J; Braquet P; Vargaftig BB
Eur J Pharmacol; 1986 Aug; 127(1-2):83-95. PubMed ID: 3019727
[TBL] [Abstract][Full Text] [Related]
16. The role of Ca2+ in regulating the catabolism of PAF-acether (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in rabbit platelets.
Touqui L; Shaw AM; Dumarey C; Jacquemin C; Vargaftig BB
Biochem J; 1987 Jan; 241(2):555-60. PubMed ID: 3109377
[TBL] [Abstract][Full Text] [Related]
17. PAF binding sites. Characterization by [3H]52770 RP, a pyrrolo[1,2-c]thiazole derivative, in rabbit platelets.
Robaut C; Durand G; James C; Lave D; Sedivy P; Floch A; Mondot S; Pacot D; Cavero I; Le Fur G
Biochem Pharmacol; 1987 Oct; 36(19):3221-9. PubMed ID: 2822048
[TBL] [Abstract][Full Text] [Related]
18. The effect of 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (paf-acether) on the arterial wall.
Bourgain RH; Maes L; Braquet P; Andries R; Touqui L; Braquet M
Prostaglandins; 1985 Aug; 30(2):185-97. PubMed ID: 3931178
[TBL] [Abstract][Full Text] [Related]
19. Conversion of 3H-PAF acether by rabbit platelets is independent from aggregation: evidences for a novel metabolite.
Touqui L; Jacquemin C; Vargaftig BB
Biochem Biophys Res Commun; 1983 Feb; 110(3):890-3. PubMed ID: 6838557
[TBL] [Abstract][Full Text] [Related]
20. 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle.
Touqui L; Jacquemin C; Dumarey C; Vargaftig BB
Biochim Biophys Acta; 1985 Jan; 833(1):111-8. PubMed ID: 3967037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
